Lead Product(s): K-NK004,Isatuximab-irfc
Therapeutic Area: Oncology Product Name: K-NK004
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Deal Size: $359.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2020
Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK cells from a healthy donor. NK cells seek and identify malignant cancer cells and have broad application across various tumor types.
Lead Product(s): Vγ9Vδ2 T cells based antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Novo Ventures
Deal Size: $83.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 17, 2020
This financing provides meaningful capital to advance Lava's bispecific gamma-delta T cell engager portfolio into multiple proof-of-concept clinical trials expected to start in 2021 for the treatment of solid tumors and hematologic malignancies.